72517-23-8

Basic information

• Product Name: 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID
• Synonyms: RARECHEM AL BE 0905;5-BROMO-2,3-DIMETHOXY-BENZOIC ACID;BUTTPARK 153\33-76;NSC 281247
• CAS NO: 72517-23-8
• Molecular Formula: C₉H₉BrO₄
• Molecular Weight: 261.07
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 72517-23-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 120 °C
• Boiling Point: 348.1°Cat760mmHg
• Flash Point: 164.3°C
• Appearance: /
• Density: 1.571g/cm³
• Vapor Pressure: 1.94E-05mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.58±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID(72517-23-8)
• EPA Substance Registry System: 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID(72517-23-8)

Safety Data

• Hazardous Substances Data: 72517-23-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-2,3-dimethoxy benzoic acid is a chemical compound with the molecular formula C9H9BrO4. It is a derivative of benzoic acid, which is commonly used in organic synthesis. 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID contains a bromine atom and two methoxy groups attached to the benzene ring. It is a white to off-white crystalline powder that is sparingly soluble in water but more soluble in organic solvents. 5-BROMO-2,3-DIMETHOXY-BENZOIC ACID has potential applications in the pharmaceutical industry and in organic synthesis as a building block for more complex molecules. It is important to handle this compound with care and use appropriate safety precautions due to its potential hazards.

InChI:InChI=1/C9H9BrO4/c1-13-7-4-5(10)3-6(9(11)12)8(7)14-2/h3-4H,1-2H3,(H,11,12)

Upstream product

• 72517-15-8 2,3-dihydroxy-5-bromobenzoic acid 
• 5653-67-8 2,3-dimethoxybenzyl alcohol 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 5034-74-2 5-bromo-3-methoxysalicylaldehyde 
• 86-51-1 2,3-dimethyoxybenzaldehyde 
• 303-38-8 2,3-Dihydroxybenzoic acid 
• 86232-53-3 3-Methyl-4,5-dimethoxyaniline 
• 83131-08-2 methyl 5-bromo-2,3-dimethoxybenzoate 
• 77-78-1 dimethyl sulfate 
• 86232-34-0 (5-bromo-2,3-dimethoxyphenyl)methanol 
• 71295-21-1 5-bromo-2,3-dimethoxybenzaldehyde 
• 7487-88-9 magnesium sulfate 
• 58005-60-0 5-bromo-2,3-dimethoxytoluene 

Downstream Products

• 1404548-74-8 5-bromo-2,3-dimethoxyaniline 
• 1404548-78-2 5-[(5-bromo-2,3-dimethoxyphenylamino)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1404548-86-2 2,3-dimethoxy-5-[(trimethylsilyl)ethynyl]aniline 
• 107188-74-9 [3H]-FLB 457 
• 407610-20-2 2-(2,3-dimethoxy-5-bromophenyl)imidazole-4-carboxaldehyde 
• 407610-17-7 N-tert-butyl-5-bromo-2,3-dimethoxybenzamide 
• 1027904-03-5 2-(5-Bromo-2,3-dimethoxy-phenyl)-5-chloromethyl-1H-imidazole 
• 407610-18-8 2-(2,3-dimethoxy-5-bromophenyl)-4-(hydroxymethyl)imidazole 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Quercetagetin Analogues as JNK1 Inhibitors

The recent discovery of c-Jun NH2-terminal kinase JNK1 suppression by natural quercetagetin (1) is a promising lead for the development of novel anticancer agents. Using both X-ray structure and docking analyses we predicted that 5′-hydroxy- (2

Synthesis of 3-(5-bromo-2,3-dimethoxy-phenyl)-[1, 2, 4] oxadiazole analogues and their evaluation as anti-Parkinson's agents

A series of 3-(5-bromo-2,3-dimethoxy-phenyl)-[1, 2, 4] oxadiazole derivatives was prepared and their evaluation for anti-Parkinson's activity was measured in vivo using albino rats. The result of the biological activity studies indicated that some of the

Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors

A series of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole derivatives was prepared and their affinity for dopamine D2 and D3 receptors was measured using in vitro binding assays. Several oxadiazole analogues were also prepared and tested for their affinity for dopamine D2 and D3 receptors. The results of receptor binding studies indicated that the incorporation of an imidazole moiety between the phenyl ring and the basic nitrogen did not significantly increase the selectivity for dopamine D3 receptors, whereas the incorporation of an oxadiazole at the same region resulted in a total loss of affinity for both dopamine receptor subtype binding sites. The most selective compound in this series is 2-(5-bromo-2,3-dimethoxyphenyl)-4-(6,7-dimethoxy-1,2,3, 4-tetrahydroisoquinolinomethyl)imidazole (5i), which has a D3 receptor affinity of 21 nM and a 7-fold selectivity for D3 versus D2 receptors. The binding affinity for σ1 and σ2 receptors was also measured, and the results showed that several analogues were selective σ1 receptor ligands.